High Lp(a): New Insights into Heart Attack & Cardiovascular Risk

Despite optimal cholesterol treatment, a significant number of individuals continue to experience cardiovascular events, and emerging research points to lipoprotein(a), or Lp(a), as a key contributing factor. Elevated levels of Lp(a) identify a residual cardiovascular risk, even in those with well-managed low-density lipoprotein cholesterol (LDL-C), commonly known as “bad” cholesterol.

Recent findings highlight the importance of assessing Lp(a) levels, as high levels can promote blood clotting and inflammation, increasing the risk of heart attack and stroke. Here’s particularly relevant as Lp(a) levels are largely genetically determined and remain relatively stable throughout a person’s life.

Lp(a): A Growing Focus in Cardiovascular Risk Assessment

For years, Lp(a) was considered a biochemical curiosity, but it has now evolved into a central player in cardiovascular risk assessment. Approximately 1.5 billion people worldwide are affected by elevated Lp(a) levels, making it a widespread concern. The recognition of Lp(a)’s role is prompting a reevaluation of how cardiovascular risk is assessed and managed.

A landmark 2024 study, following nearly 28,000 U.S. Women for 30 years, demonstrated that women in the highest quintile of baseline Lp(a) levels had a 33% increased adjusted hazard ratio for experiencing a first major cardiovascular event – including myocardial infarction, coronary revascularization, stroke, or cardiovascular death – compared to those in the lowest quintile. This effect remained independent of high-sensitivity C-reactive protein (hsCRP) and LDL-C levels.

Genetic Predisposition and Ethnic Variations

Plasma concentrations of Lp(a) are approximately 70-90% genetically determined, meaning an individual’s Lp(a) level is largely predetermined. This genetic component also contributes to substantial ethnic differences. Concentrations are lowest in people of Chinese, European, and Southeast Asian descent, intermediate in those of South Asian descent, and highest in Black individuals.

Lp(a) concentrations are 17% higher in postmenopausal women than in men. These variations underscore the need for personalized risk assessment and potentially tailored treatment strategies.

Residual Risk and Limited Treatment Options

The challenge lies in addressing the residual cardiovascular risk that persists even when LDL-C levels are optimally controlled with medication. Current LDL-C-affecting drugs have a limited effect on Lp(a) levels, leaving a gap in treatment options for individuals with high Lp(a).

Sandra Revill Tremulis, a patient advocate who discovered her high Lp(a) level after a near-fatal heart attack, emphasized the importance of awareness and diagnosis. She noted that the Centers for Disease Control and Prevention (CDC) recognized high Lp(a) levels as a clinical diagnosis in 2018, establishing billing and payment codes for related clinical work and lab testing. “I wanted to make sure that there’s help for every child who inherits this so that they can change their cardiovascular destiny,” she said.

The Need for Further Research and Targeted Therapies

The growing understanding of Lp(a)’s role in cardiovascular disease is driving research into targeted therapies. While current treatments primarily focus on lowering LDL-C, there is a pressing need for interventions specifically designed to reduce Lp(a) levels and mitigate the associated risks. The development of such therapies could significantly improve outcomes for individuals with elevated Lp(a) and reduce the burden of cardiovascular disease worldwide.

The identification of Lp(a) as a significant independent risk factor represents a crucial step forward in personalized cardiovascular care, prompting a shift towards more comprehensive risk assessment and the pursuit of novel therapeutic strategies.